alzheimer

Second South Texas Alzheimer's Conference convenes Feb. 23-25 in San Antonio

“We want to increase Hispanic enrollment in clinical trials. One of our goals is to understand the disease in this growing population.” — Sudha Seshadri, M.D., founding director, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio

SAN ANTONIO (PRWEB) February 14, 2020
Health care professionals, scientists and students interested in collaboration and discussion on transformational care, research and therapeutics in Alzheimer’s disease are invited to the 2nd Annual South Texas Alzheimer’s Conference Feb. 23-25 in San Antonio.
To register and for a complete agenda, visit BiggsInstitute.org.
The conference is presented by the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases in partnership with the Alzheimer’s Association. The Biggs Institute is part of the Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio).
The conference will begin with an opening reception and dinner on Sunday, Feb. 23, at UT Health San Antonio, and will shift venues to the Briscoe Western Art Museum in downtown San Antonio for daylong sessions Monday and Tuesday, Feb. 24 and 25.
Themes will include:
Alzheimer’s disease in the Hispanic population;
Precision omics;
Cognitive and neuroimaging approaches to the diagnosis, prevention and treatment of dementia; and
Novel approaches to the care and treatment of patients and care partners including home-based care.
Scheduled plenary presentations are:

“Technology to Advance Assessments and Interventions for Dementia” by Jeffrey Kaye, M.D., Layton Endowed Professor of Neurology and Biomedical Engineering at Oregon Health and Science University. Dr. Kaye directs the NIA-Layton Oregon Aging and Alzheimer’s Disease Research Center and the Oregon Center for Aging and Technology, which incorporates the NIA-Oregon Roybal Center for Care Support Translational Research Advantaged by Integrating Technology.
“Alzheimer’s Prevention and Preparedness: Addressing Disparities” by Kristine Yaffe, M.D., chief of neuropsychiatry and director of the Memory Evaluation Clinic at the San Francisco Veterans Affairs Medical Center. Dr. Yaffe occupies the Scola Endowed Chair, is vice chair and professor of psychiatry, neurology and epidemiology, and director of the Center for Population Brain Health at the University of California, San Francisco.
“Inter-ethnic Differences in Prevalence of Cognitive Impairment” by Christopher Chen, BA, BMBCh, MRCP, FAMS, FRCPE, senior clinician-scientist and associate professor in the Departments of Pharmacology and Psychological Medicine at the National University of Singapore, and director of the Memory Aging and Cognition Centre at the National University Healthcare System.
“An Overview of Promising New Approaches to Preventing and Treating Dementias” by Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and the Robert R. Barker Distinguished University Professor of Neurology, Psychiatry, and Cellular and Integrative Physiology at UT Health San Antonio. Dr. Seshadri is senior investigator of the Framingham Heart Study.
The Hispanic/Latino population is at increased risk of Alzheimer’s/dementia. Addressing this is a major point of emphasis for the conference speakers. “This is one reason why we want to increase Hispanic enrollment in clinical trials,” Dr. Seshadri said. “One of our goals at the Glenn Biggs Institute, and worldwide, is to understand the disease in this growing population.”
The Long School of Medicine at The University of Texas Health Science Center at San Antonio is named for Texas philanthropists Joe R. and Teresa Lozano Long. The school is the largest educator of physicians in South Texas, many of whom remain in San Antonio and the region to practice medicine. The school teaches more than 900 students and trains 800 residents each year. As a beacon of multicultural sensitivity, the school annually exceeds the national medical school average of Hispanic students enrolled. The school’s clinical practice is the largest multidisciplinary medical group in South Texas with 850 physicians in more than 100 specialties. The school has a highly productive research enterprise where world leaders in Alzheimer’s disease, diabetes, cancer, aging, heart disease, kidney disease and many other fields are translating molecular discoveries into new therapies. The Long School of Medicine is home to a National Cancer Institute-designated cancer center known for prolific clinical trials and drug development programs, as well as a world-renowned center for aging and related diseases.
The University of Texas Health Science Center at San Antonio, dba UT Health San Antonio, is one of the country’s leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit http://www.uthscsa.edu.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Share article on social media or email:

Diagnomics Introduces HealthLytix Alzheimer's Disease Risk Assessments Through GenoMatch.Me Employee Benefits Program

Press Release – updated: Feb 12, 2020 07:00 PST

SAN DIEGO, February 12, 2020 (Newswire.com) – Diagnomics Inc. (www.diagnomics.com), a San Diego-based genetic testing company, announced today that they will be launching HealthLytix (www.healthlytix.com) Alzheimer’s risk assessment products on the GenoMatch.Me platform for employee wellness. By 2050, it is estimated there will be as many as 16 million Americans living with Alzheimer’s disease, and the total lifetime cost of care for someone with dementia is estimated to be just over $350K (2018 Alzheimer’s Disease Facts and Figures). The recent boom in direct-to-consumer genetic testing has given people the opportunity to understand their risk for this devastating disease and have a chance at early diagnosis, which is key to better outcomes. HealthLytix Alzheimer’s GeneticRisk(™) is the most comprehensive genetic analysis to hit the market, looking beyond APOE status at approximately 200,000 other common genetic variants to predict the risk of late-onset Alzheimer’s disease as a function of age.
HealthLytix hopes that making this test more widely available will empower people to be more proactive about their health. “Lifestyle is key in influencing an individual’s risk, and early risk identification provides greater opportunity for intervention and risk mitigation,” says Dr. Christine Swisher, Director of Science and Engineering at HealthLytix. “To accomplish the early identification of at-risk individuals, prediction must rely on evidence prior, such as genetics are present prior to the onset of symptoms,” she adds.
“We are excited to add HealthLytix’s Alzheimer’s GeneticRisk to the GenoMatch.Me healthcare report portfolio. Our team has put in continuous effort to bring consumer genomics products that enable a proactive approach to preventive health and disease risk management. Recognizing Alzheimer’s risk can be instrumental in potentially increasing early intervention rates and improving quality of life factors.” Min Seob Lee, PhD, Chairman of Diagnomics commented. GenoMatch.Me is an e-commerce platform offered by Diagnomics that is available to corporate clients providing personalized genetic testing services as a health benefit program. The company empowers precision medicine in healthcare and wellness by pioneering innovative genomic technologies to provide clinically actionable guidance to physicians and patients for better treatment and prevention management.
About Diagnomics
Diagnomics Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. Diagnomics strives to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market. Diagnomics is a CLIA-certified, CAP-accredited laboratory providing genetic testing platform services and highly secure HIPAA-compliant, cloud-based analysis solutions. To learn more, visit www.diagnomics.com.
About HealthLytix
At HealthLytix, we’re developing cutting-edge advances in genetics and medical imaging to revolutionize disease screening and early detection so people can enjoy longer, healthier lives while reducing healthcare costs. Learn more about our personalized genetic and integrated reports, and advanced imaging solutions at www.healthlytix.com.
Source: Diagnomics Inc.

2020 Best of Senior Living Award Presented to Cardinal Court Alzheimer's Special Care Center

Press Release – updated: Feb 11, 2020 15:50 EST

STRONGSVILLE, Ohio, February 11, 2020 (Newswire.com) – Cardinal Court Alzheimer’s Special Care Center is proud to announce that they have been selected as one of 2020’s Best of Senior Living Award Winner on SeniorAdvisor.com, the largest ratings and reviews site for senior care in North America and Canada. The winners are based on the online reviews written by seniors and their families. This exclusive designation honors the top 2-3% of senior care providers across the United States and Canada. Out of the over 240,000 family reviews, this award is granted to only 610 senior care providers.
Cardinal Court is a community devoted to helping those living with memory loss. If a loved one is living with Alzheimer’s or another form of dementia, their dedicated focus on the population can help them continue living lives of meaning and purpose. It’s located in the scenic Cleveland suburb of Strongsville, Ohio, a city that blends small-town charm with a vibrant business community and is just minutes away from all of the excitement of big city life.
What sets Cardinal Court apart from other assisted living communities is its Meaningful Moments®. This program, designed for those living with memory loss, is unique to JEA Senior Living and is built on learning all they can about the residents in order to create a homelike environment in which they feel comfortable cared for. The compassionate staff takes the time to discover loved one’s interests, desires, and life story to develop a personalized care plan designed to ensure they continue to live a life of purpose and joy.
Their holistic approach to care includes developing partnerships with family members and other health care providers to ensure to meet their physical, social, emotional, mental and spiritual needs. They create an environment that residents and family members alike are happy to call home.
As the recipient of this prestigious award, Cardinal Court is honored to uphold the highest quality of care for those living with dementia. As a deficiency-free community, they have a mission to honor the experience of aging. Cardinal Court looks forward to continuing to serve the Greater-Cleveland area as the experts in dementia care. 
Source: Cardinal Court Alzheimer’s Special Care Center

Gladstone Scientists Funded by NIH to Dive Deep Into ApoE4's Role in Alzheimer's Disease

With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer’s disease.
SAN FRANCISCO, January 29, 2020 (Newswire.com) – The story of Alzheimer’s disease is familiar and heartbreaking. As neurons degenerate and die, patients slowly lose their memories, their thinking skills, and ultimately, their ability to perform basic day-to-day tasks.
For years, clinical trials investigating potential treatments for Alzheimer’s disease have come up short. That’s why researchers at Gladstone Institutes are delving deeper into the question of what drives this complex disease.
Now, a team led by Senior Investigator and President Emeritus Robert Mahley, MD, PhD, has received $4.8 million from the National Institutes of Health (NIH) to study a promising culprit: apoE4, a protein associated with increased risk of Alzheimer’s disease.
ApoE4 is one of the forms of apolipoprotein E, a protein that aids repair processes in neurons injured by aging, stroke, or other causes. The most common form is called apoE3, but apoE4 is not rare: it is found in one-quarter of the human population and in about two-thirds of all Alzheimer’s patients, which makes it the most important genetic risk factor for the disorder.
“ApoE4 dramatically rewires cellular pathways in neurons and impairs their function,” Mahley said. “Our goal is to understand how this rewiring occurs and identify potential new treatment strategies to negate the detrimental effects.”
ApoE3 and apoE4 differ at only a single point in the sequence of their amino acid building blocks. But that single change gives apoE4 a very different shape from apoE3, making it more susceptible to being broken down into smaller fragments within a neuron.
“Our work suggests that these apoE4 fragments are toxic to neurons and cause sweeping changes to the collection of proteins expressed within a neuron,” Mahley said. “We suspect that their toxicity may underlie much of the neurodegeneration seen in Alzheimer’s disease.”
A Powerful Partnership
With the new NIH funding, Mahley hopes to illuminate the specifics of apoE4’s toxicity in unprecedented molecular detail. Key to this work is his new partnership with Senior Investigator Nevan Krogan, PhD, and Gladstone Mass Spectrometry Facility Director Danielle Swaney, PhD, who together have extensive expertise in studying how proteins interact with each other.
To get to the bottom of apoE4’s impact, they will use a technique called affinity purification mass spectrometry (AP-MS) to first determine which proteins, out of the thousands found in a single cell, interact directly with apoE4 fragments.
“AP-MS is an important first step because it will allow us to define physical interactions between proteins that may underlie the functional deficits observed in neurons that express apoE4,” Swaney said. The AP-MS work will be performed in mouse-derived neuronal cells that are similar to human neurons.
In addition to AP-MS, the collaborators will use other advanced protein analysis techniques perfected in Krogan’s lab to better understand the cellular processes that are dysregulated in apoE4-expressing neurons. This additional protein work will be performed in neurons derived from human induced pluripotent stem (hiPS) cells. These stem cells are produced from human skin cells, using the procedure developed by Shinya Yamanaka, MD, PhD, a Gladstone senior investigator and 2012 Nobel prize winner.
“We are quite excited to be involved in this project,” Krogan said. “My lab has successfully applied AP-MS and other cutting-edge proteomic and genetic techniques to many different diseases, and we now hope to enable a much deeper understanding of apoE4.”
When combined, results from the APMS work and the additional protein analyses will reveal a list of key proteins involved in processes that are specifically altered in apoE4 neurons compared to apoE3 neurons.
From that list, Mahley and Swaney will select top candidates for further investigation in neurons grown from hiPS cells. Senior Investigator Yadong Huang, MD, PhD, who has also studied apoE4 extensively, will provide guidance on the use of the hiPS cells.
Using a gene-editing tool called CRISPR, the researchers will see if they can reverse the detrimental effects of apoE4 by activating or inhibiting genes that control their top candidate proteins in the hiPS cell-derived neurons. Finally, they will validate the findings in mice.
“By the end of the project, we hope to narrow down our list to just a few target genes or proteins that protect or restore neuronal health when we activate or inhibit them in live mice with the apoE4 gene,” Swaney said. “They could then be explored as potential targets for Alzheimer’s treatment in humans.”
New Hope for Alzheimer’s Disease
Mahley and Swaney already have some ideas about where this work may lead. Earlier this year, they published evidence that apoE4 broadly impacts the mitochondria—organelles that produce the energy that powers a cell—and perturbs normal energy production.
“Anything could be a target at this point, but I’m particularly interested in the possibility of small-molecule drugs that could protect mitochondria from toxic apoE4 fragments,” Mahley said.
Still, mitochondria are just one aspect of the bigger picture. Mahley suspects that what we call “Alzheimer’s disease” is actually a collection of related conditions with different underlying causes for different patients.
“Ultimately, I think the treatment of Alzheimer’s disease will be similar to the treatment of high blood pressure, in that two, three, sometimes four drugs are needed to control the disorder,” he said. “So, we may need a mitochondrial protector, we may need a drug that will correct apoE4’s shape so that it is more like apoE3, and more.”
Understanding the complex effects of apoE4—as well as the other Alzheimer’s disease-associated factors being explored at Gladstone—could one day enable just such a comprehensive approach.
Media Contact:Megan McDevitt​megan.mcdevitt@gladstone.ucsf.edu415.734.2019
Source: Gladstone Institutes

River Oaks Alzheimer's Special Care Center Offers a Chance to Experience What It's Like Living With Dementia

Press Release – updated: Jan 24, 2020 16:00 EST

MIAMI TOWNSHIP, Ohio, January 24, 2020 (Newswire.com) – Dementia Live® is a high-impact, dementia simulation experience that immerses participants into life with dementia, resulting in a deeper understanding of what it’s like to live with cognitive impairment and sensory change.
This is a 30-minute program with certified Dementia Live® trainers, offering a unique inside-out understanding of dementia and aging.
Participants will gain a heightened awareness of the challenges faced by those living with dementia. Learn valuable tips and tools to improve communication and care.
Dementia Live®, Jan. 30, 2020 available at the following times: 1:00 p.m., 1:30 p.m., 2:00 p.m., 2:30 p.m.
Pre-registration is required.RSVP to Susie Dudley at 937-291-1100 or at susanna.dudley@jeaseniorliving.com with your preferred time.
This event will be held at River Oaks Alzheimer’s Special Care Center.
A Tradition of Caring Together2961 West Spring Valley Pike, Miamisburg, OH 45342 | 937-291-1100 | jeaseniorliving.com
Source: River Oaks Alzheimer’s Special Care Center

New Small Molecule to Treat Alzheimer's Disease and Dravet Syndrome

New study shows potentiating a subset of NMDA receptors may be beneficial in Alzheimer’s disease and Dravet syndrome.
Press Release – updated: Jan 14, 2020 12:57 PST

SAN FRANCISCO, January 14, 2020 (Newswire.com) – Gladstone researchers, in collaboration with Genentech, a member of the Roche group, have shown therapeutic efficacy of a new experimental drug in mouse models of Alzheimer’s disease and a rare genetic form of epilepsy known as Dravet syndrome. The small molecule increases the activity of a subset of neurotransmitter (NMDA) receptors that are found at synapses, the connection points between neurons. These receptors are known to support cognition and memory by enhancing communication between neurons. The new research shows that enhancing the activity of synaptic NMDA receptors helps restore the brain’s rhythms to normal patterns, and improves memory.
“Before now, we haven’t had ideal tools to enhance synaptic NMDA receptors,” said Gladstone Associate Investigator Jorge Palop, Ph.D., senior author of the study, which was published in the journal Cell Reports. “Now, the ability to specifically target these receptors opens up a lot of new possibilities for treating cognitive disorders.”
“This is the first time we’ve explored what this type of experimental drug does in animal models,” said Jesse Hanson, a scientist at Genentech and lead author of the new paper. “It was very gratifying to see an effect on both the brain’s electrical activity and the animals’ behavior.”
Abnormal activity of NMDA receptors has been long implicated in neuropsychiatric, epileptic, and neurodegenerative disorders. But previous compounds for altering NMDA receptor function worked by binding to all subtypes of NMDA receptors, and either completely blocked the receptors or put them in a permanently active state. Researchers have theorized that modulating the receptors only at active synapses may help diverse cognitive diseases by potentiating synaptic function and increasing neuronal communication.
In 2016, Genentech researchers first reported the development of a new class of experimental drugs that selectively bound to one subtype of NMDA receptors—those found only at the synapses. The new drug was also unique because rather than directly activating the receptors, it amplified the receptors’ signals primarily when engaged by neurotransmitters, the chemicals neurons use to communicate with each other.
“These compounds enhance naturally occurring activity at the synapses, rather than turning the receptors on all the time,” said Keran Ma, a staff scientist at Gladstone and a co-first author of the paper. “Thus, active synapses are potentiated in a more physiologically relevant way.”
Gladstone and Genentech researchers teamed up to test the effect of one of the new experimental drugs, GNE-0723, on mouse models of Alzheimer’s disease and Dravet syndrome. In the new paper, they report that GNE-0723 reduced a type of brain activity called low-frequency oscillations. These oscillations occur naturally even in healthy people, but are more prominent in Alzheimer’s disease and Dravet syndrome, and can be associated with epileptic brain activity, which can contribute to impaired cognition and memory loss. When the researchers treated mice simulating Alzheimer’s disease or Dravet syndrome with GNE-0723, low-frequency oscillations returned to levels seen in healthy control mice, and epileptic activity ceased.
“What we saw after the treatment were brain-wide changes in neural activity that shift the brain to a more active state that facilitates learning and memory,” said Palop, who is also an associate professor of neurology at UC San Francisco.
Indeed, after diseased mice were treated with the experimental drug for several weeks, they performed better in learning and memory tests than untreated animals—they both learned faster and retained memories longer.
Two different types of brain cells—interneurons and excitatory cells—have NMDA receptors, and future studies will address which cell type is responsible for the beneficial effects of GNE-0723.
At Genentech, Hanson also explained that more research is needed to understand how this class of experimental drugs affects brain function. “For now, we’re focused on using GNE-0723 as a research tool to learn what happens when you enhance NMDA receptors,” Hanson said. “This is a powerful tool to understand both basic biology and disease mechanisms.”
Media ContactMegan McDevitt, Vice President of CommunicationsDirect line: 415.734.2019​
Source: Gladstone Institutes

Fontella Bateman's New Book 'Sarah's Alzheimer's Story' is a Helpful Key in Knowing How to Act and Give Love and Care to Someone Who Struggles With Alzheimer's

Recent release “Sarah’s Alzheimer’s Story” from Covenant Books author Fontella Bateman is a heartfelt and honest retelling of Sarah and her family’s journey with Alzheimer’s, which also speaks of their love for one another and their unity as they walked this rough path.
Press Release – updated: Jan 10, 2020 06:00 EST

PASADENA, Md., January 10, 2020 (Newswire.com) – Fontella Bateman, a part-time administrative assistant in the Department of Modern Languages, Linguistics, and Intercultural Communication at University of Maryland, Baltimore County, has completed her new book, “Sarah’s Alzheimer’s Story”: a comforting read that brings tips and ideas that will help one find a way to take care of a loved one who has Alzheimer’s or dementia.
Fontella shares, “In telling Sarah’s Alzheimer’s Story, the writer takes you back to where it all began in the hills of Kentucky where Sarah was born. You may laugh, cry, or simply wonder as you go with her through her journey of life.
The reader will get to know about the strong woman Sarah and how she endures many tragedies. One will find that even though memory loss is a large part of Alzheimer’s disease, in Sarah’s case, there is so much more.
Throughout the story, the writer sometimes takes you back to incidents earlier in Sarah’s life. In the writer’s opinion, Sarah may be recalling something from the past, causing her to act the way she does. This seems to be especially true when she begins to see or talk to imaginary people. Dealing with this disease is often a struggle for Sarah and her family. But hopefully, you will see the joy in their laughter, the sorrow in their tears, and feel their strong love.
It is hard to watch this very strong woman deteriorate mentally, physically, and lose her personality. But this writer believes that there is a reason, even if we do not understand it at the time.”
Published by Covenant Books of Murrells Inlet, South Carolina, Fontella Bateman’s new book shares to the readers a touching memoir of a woman who suffered with Alzheimer’s. This will inspire them with her family’s beautiful story which is also written in the hopes of reaching those who face a similar situation.
Readers can purchase “Sarah’s Alzheimer’s Story” at bookstores everywhere, or online at the Apple iTunes Store, Amazon, or Barnes & Noble.
Covenant Books is an international Christian owned and operated publishing house based in Murrells Inlet, South Carolina. Covenant Books specializes in all genres of work which appeal to the Christian market. For additional information or media inquiries, contact Covenant Books at 843-507-8373.
Source: Covenant Books

Mount Pleasant Alzheimer's Special Care Center Offers a Chance to Experience What It's Like Living With Dementia

Mount Pleasant Gardens Offers Caregivers a Chance to Experience What It’s Like Living with Dementia
Press Release – updated: Jan 6, 2020 16:12 EST

MOUNT PLEASANT, S.C., January 6, 2020 (Newswire.com) – Mount Pleasant Gardens, a leader in providing quality care and housing services to people living with memory loss, is hosting a special event designed to help caregivers experience the challenges of living with dementia. Dementia Live is an innovative program designed by a team of dementia experts from AGE-u-cate Training Institute. This special event will be held at 3:00 p.m. to 5:00 p.m. on Wednesday, Jan. 8, 2020 at the community located at 1025 Hungryneck Blvd. Mount Pleasant, SC 29464.
Dementia Live uses special gear to help simulate the cognitive impairments and sensory changes that are part of living with dementia. Participants will gain a sense of the obstacles and difficulties those living with dementia face daily.
“The goal of this program is to give caregivers a greater sense of understanding and empathy for what their loved ones face every day,” says Leanne Lovin, Community Resource Director. “By having a greater understanding, we hope to foster a greater sense of compassion, helping caregivers to provide better support for the ones they love.”
If you are interested in attending this special event, please call Mount Pleasant Gardens 843-216-1001. To learn more about Dementia Live or our memory care, please visit https://www.jeaseniorliving.com/senior-living/sc/mount-pleasant/mt-pleasant-gardens/contact-us.
Source: Mount Pleasant Gardens Alzheimer’s Special Care Center

The Judy Fund and Compass Combating Alzheimer’s Together

Elizabeth Stearns

We hit that goal in our very first year, and over the next 10 years raised more than $2 million for our community. Now we are part of the larger Compass Cares organization, but our local fundraising is now around $1 million per year and our national goals are over $10 million per year.

LOS ANGELES (PRWEB) December 02, 2019
Stearns’ firm, Partners Trust, was founded in 2009 with the goal of creating a revolutionary real estate culture that required and expected associates to perform at the highest professional and ethical level. Partners Trust later became part of the Compass family in 2018. Compass is now the largest independent real estate brokerage firm in the country.
“We started the Charitable Giving Fund at Partners Trust in 2009. Our goal was to raise at least $100,000 per year and give it to local organizations and charities in the fields of education, arts, healthcare and children’s care,” said Stearns. “We hit that goal in our very first year, and over the next 10 years raised more than $2 million for our community. Now we are part of the larger Compass Cares organization, but our local fundraising is now around $1 million per year and our national goals are over $10 million per year.”
This year, The Judy Fund was honored to be chosen as one of the three charities selected as a beneficiary by The Compass/PartnersTrust Charitable Foundation, which has granted funds to over 100 organizations to date. Compass, Los Angeles is a major supporter of The Judy Fund and Walk to End Alzheimer’s.
Richard’s wife, Elizabeth Stearns, chaired and organized The Judy Fund Team during the recent Walk to End Alzheimer’s, and agents and staff of Compass supported the annual team by walking with them and assisting with additional fundraising. The Judy Fund National Walk Team had 42 teams nationwide this year and has raised $64,300 to date.
“Together we are helping the Alzheimer’s Association search for a cure and care for those who are living with or are affected by the disease through the support of our local chapters,” said Elizabeth.
Elizabeth is a nationally recognized advocate for the advancement of Alzheimer’s disease research and care. Elizabeth’s mother Judy Gelfand was diagnosed with Alzheimer’s at the age of 62, and passed away at 70. In response to the initial diagnosis, Elizabeth, who spent 16 years at Universal Pictures, transitioned from her role to partner with her father, Marshall Gelfand, on the development of The Judy Fund.
To date, the fund has raised and granted $8.5 million to support the research, care and advocacy efforts of the Alzheimer’s Association. In fact, it is the largest and fastest growing fund in the history of the Alzheimer’s Association. Today, The Judy Fund has more than 2,500 donors nationwide and a new goal to raise $10 million by 2020.
About The Judy FundMarshall M. Gelfand and his family established The Judy Fund at the Alzheimer’s Association in 2003 in loving memory of his wife, Judy Gelfand. Its mission is to help create Alzheimer’s survivorship for future generations. Through the generosity of families, friends, business colleagues and corporations, The Judy Fund, now chaired by Elizabeth Gelfand Stearns, remains the fastest and largest growing family fund at the Alzheimer’s Association.
About Richard Stearns, CompassRichard Stearns is consistently recognized as a top producer by The Wall Street Journal and named to both Variety Magazine’s Los Angeles Real Estate Elite and Hollywood Reporter’s Top 25 Real Estate Agents. Compass agents are leaders in their markets, consistently ranking highest in customer satisfaction and revenues. For more information, please call (310) 850-9284, or visit http://www.compass.com.
For media inquiries, please call THE NALA at 805.650.6121, ext. 361.

Share article on social media or email:

Hickory Hills Alzheimer's Special Care Center Offers a Chance to Experience What It's Like Living With Dementia

Press Release – updated: Nov 26, 2019 16:46 EST

HENDERSONVILLE, Tenn., November 26, 2019 (PressRelease.com) – Hickory Hills Alzheimer’s Special Care Center, a leader in providing quality care and housing services to people living with memory loss, is hosting a special event designed to help caregivers experience the challenges of living with dementia. Dementia Live is an innovative program designed by a team of dementia experts from AGE-u-cate Training Institute. This special event will be held at 2:30 to 4:30 PM on Tuesday, Dec. 3 at the community located at 162 Indian Lake Blvd, Hendersonville TN 37075.
Dementia Live uses special gear to help simulate the cognitive impairments and sensory changes that are part of living with dementia. Participants will gain a sense of the obstacles and difficulties those living with dementia face on a daily basis.
 “The goal of this program is to give caregivers a greater sense of understanding and empathy for what their loved ones face every day,” says Marisa Parker, Administrator. “By having a greater understanding, we hope to foster a greater sense of compassion, helping caregivers to provide better support for the ones they love.”
If you are interested in attending this special event, please call the Hickory Hills Special Care Unit at 615.266.4473 or contact us online here:  https://1ad.biz/s/HickoryHills